Zolmitriptan with Adhesive Dermally Applied Microarray (ADAM) produces consistently better headache responses among migraineurs with nausea, severe headache, migraine present upon awakening and treatment ≥2 hours after migraine onset, evident from the post hoc analysis of data from the ZOTRIP trial.

In the pivotal Phase 2b/3 study, 3.8 mg ADAM Zolmitriptan was used to provide superior pain freedom and freedom from patients' common most bothersome associated symptom (MBS). The same dose was followed in this post hoc subgroup analyses. The number of migraineurs with severe headache was 72, with nausea was 110, with migraine during awakening was 80 and whose treatment gets delayed two or more hours following onset was 75. Whether these patients got superior treatment outcomes with  ADAM Zolmitriptan 3.8 mg as compared to placebo were determined using the Cochran-Mantel-Haenszel test. The ADAM Zolmitriptan 3.8 mg group showed a higher number of patients who achieved 2-hour pain freedom and 2-hour MBS freedom as compared to the placebo groups.

Moreover, patients with all migraine characteristics showed better outcomes with ADAM Zolmitriptan 3.8 mg as compared to the placebo. Subgroup interaction exhibited no significant effects in logistical regression models of treatment.

The study concluded that ADAM Zolmitriptan can be an effective management option for the migraine characteristics that had been hard to manage.